+1 877 302 8632
+1 888 205 9894 (Toll-free)

SARS-CoV-2 Nucleocapsid anticorps (SARS-CoV-2 N) Primary Antibody

SARS-CoV-2 N Reactivité: SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2) ELISA, IF Hôte: Lapin Chimeric CR3018 (03-018)
Pubmed (1)
N° du produit ABIN6953059
Plus shipping costs $45.00
200 μg
local_shipping Destination: Etats-Unis
Envoi sous 7 à 11 jours ouvrables
  • Antigène
    Type d'anticorp
    Recombinant Antibody
    SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
    Cet anticorp SARS-CoV-2 Nucleocapsid est non-conjugé
    ELISA, Immunofluorescence (IF)
    This antibody binds the amino acid residues between 11-19 of the N protein of the SARS CoV as well as SARS-CoV-2 (COVID-19) nucleocapsid protein.
    Attributs du produit
    Recombinant monoclonal antibody to Covid-19 & SARS-CoV Nucleoprotein.

    Several anti-SARS-CoV-2 Nucleoprotein antibodies based on clone CR3018 are available:
    Human IgG1, IgG2, IgG3, IgA and IgM for use in neutralization assays and as serological controls
    • ABIN6953057 - Human IgG1
    Rabbit IgG, mouse IgG2b and mouse IgM for detection applications, co-labelling studies and animal model research
    • ABIN6953059 - Rabbit IgG
    Protein A affinity purified
    The original antibody was generated by cloning the variable regions of the scFvs selected from phage display libraries into separate vectors for IgG1 heavy-chain and light-chain expression. The harvested supernatents were then purified on protein A columns.
    CR3018 (03-018)
  • Indications d'application
    This antibody is recommended for detection of SARS CoV2 protein N (nucleoprotein). This antibody binds both the nucleocapsid protein of the SARS-CoV and SARS CoV-2 (2019-nCoV). Initial characterization of the antibody for binding to 2019-nCoV was done using ELISA. This antibody shows potential to be used for development of diagnostic assays. Various isotype versions of the antibody namely human IgG1, IgG3, IgM, IgA and the less common IgG2 and IgG4 are available for the investigation of their role in response to SARS CoV2. Competitive ELISA of this antibody with CR3009 suggests that both these antibodies bind different epitopes of the N protein of SARS CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Immunofluorescence staining was used to demonstrate binding of CR3018 to SARS-CoV infected Vero cells.

    Competitive ELISA of both anti-nucleocapsid antibodies suggests that they bind different, non-overlapping epitopes of the N protein of SARS-CoV. Thus, a combination of these two antibodies is suggested for virus capture assays. Clone CR3018 binds the amino acid residues between 11-19 of the N protein of SARS-CoV, while clone CR3009 binds a non-linear/conformational epitope of the N protein of SARS-CoV, both of which are sufficiently conserved to permit binding of these antibodies to SARS-CoV-2.

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    For Research Use only
  • Format
    1 mg/mL
    PBS with 0.02 % Proclin 300.
    Agent conservateur
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    4 °C,-20 °C
    Stockage commentaire
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • van den Brink, Ter Meulen, Cox, Jongeneelen, Thijsse, Throsby, Marissen, Rood, Bakker, Gelderblom, Martina, Osterhaus, Preiser, Doerr, de Kruif, Goudsmit: "Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus." dans: Journal of virology, Vol. 79, Issue 3, pp. 1635-44, 2005 (PubMed).

  • Antigène
    Autre désignation
    SARS-CoV-2 Nucleocapsid Protein
    NP, NC, Protein N, Nucleocapsid protein, SARS-CoV Protein N, SARS-CoV Nucleocapsid protein, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
Vous êtes ici: